Skip to Content

Janus Henderson Global Life Sciences D JNGLX

Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 73.60  /  −0.38 %
  • Total Assets 5.1 Bil
  • Adj. Expense Ratio
    0.800%
  • Expense Ratio 0.800%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Limited
  • TTM Yield 0.12%
  • Turnover 34%

USD | NAV as of May 24, 2024 | 1-Day Return as of May 24, 2024, 11:13 PM GMT+0

Morningstar’s Analysis JNGLX

Will JNGLX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Janus Henderson Global Life Sciences D's Average People Pillar and Process Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JNGLX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 38.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

7.06 379.0 Mil
Healthcare

UnitedHealth Group Inc

5.85 313.7 Mil
Healthcare

Novo Nordisk A/S Class B

5.18 277.7 Mil
Healthcare

Merck & Co Inc

3.63 194.8 Mil
Healthcare

AstraZeneca PLC

3.57 191.9 Mil
Healthcare

AbbVie Inc

3.36 180.2 Mil
Healthcare

Sanofi SA

2.49 133.7 Mil
Healthcare

Boston Scientific Corp

2.31 123.8 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.30 123.5 Mil
Healthcare

Abbott Laboratories

2.27 121.6 Mil
Healthcare